Literature DB >> 28357093

Triple-phase 99mTc-3P-RGD2 imaging of peripheral primitive neuroectodermal tumor in the hip muscle group with bone metastasis.

Jingjing Fu1, Jinhua Song2, Youcai Zhao3, Feng Wang1, Guoqiang Shao1.   

Abstract

Peripheral primitive neuroectodermal tumors (pPNETs) are a group of aggressive neoplasms that are most commonly encountered in pediatric patients and may be located in the abdomen, pelvis, thoracopulmonary region and, rarely, in the head and neck region. pPNETs in adults are extremely rare. The present study reports a case of pPNET located in the hip muscles with bone metastasis. The patient was a 44-year-old woman who complained of progressive pain and swelling with a mass near the left hip. Computed tomography (CT) and enhanced CT revealed a soft tissue mass lesion in the hip muscle group measuring 4.3×4.3×4.4 cm. The lesion was ill-defined, heterogeneous, exhibiting mild post-contrast enhancement. There was a large number of bent neovessels and several branches from the left internal iliac artery and deep femoral artery on enhanced CT scan. Triple-phase dynamic imaging with integrin αvβ3-targeted 99mTc-3P-RGD2 as the radiotracer revealed increased blood perfusion and radiotracer aggregation in the large, ill-defined, heterogeneous, hypodense mass and adjacent bone. The patient was suspected of having pPNET with bone metastasis, which was confirmed by histological examination of a sample obtained by needle aspiration. Due to the high blood perfusion of primary pPNETs and high RGD uptake by the primary and metastatic lesions, chemoembolization and anti-angiogenic therapy were considered to be the optimal therapeutic choice. This also suggested that 177Lu-labeled RGD has great potential for the targeted treatment of pPNETs with multiple metastases.

Entities:  

Keywords:  bone metastasis; integrin αvβ3; molecular imaging; peripheral primitive neuroectodermal tumor

Year:  2016        PMID: 28357093      PMCID: PMC5351741          DOI: 10.3892/mco.2016.1119

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  21 in total

Review 1.  Ewing's sarcoma and peripheral primitive neuroectodermal tumor: an interim report.

Authors:  J G Batsakis; B Mackay; A K el-Naggar
Journal:  Ann Otol Rhinol Laryngol       Date:  1996-10       Impact factor: 1.547

2.  Primitive neuroectodermal tumor of lungs in adults: a rare series of three cases treated with upfront chemo-radiation.

Authors:  Abhishek Purkayastha; Abhishek Pathak; Neelam Sharma; Sundaram Viswanath; Vibha Dutta
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  Management of Primitive Neuroectodermal Tumor of the Kidney with Inferior Vena Cava Thrombus.

Authors:  Sahil Gupta; Kaustav Majumder; Anurag Chahal; Ashish K Saini; Arjun Gupta
Journal:  Curr Urol       Date:  2016-02-10

4.  A peripheral primitive neuroectodermal tumor in the larynx: A case report and literature review.

Authors:  Kei Ijichi; Toyonori Tsuzuki; Makoto Adachi; Shingo Murakami
Journal:  Oncol Lett       Date:  2015-12-09       Impact factor: 2.967

5.  Peripheral primitive neuroectodermal tumor in masseter muscle.

Authors:  Haşmet Yazc; Barş Yiğit; Sedat Doğan; Ahmet Volkan Sunter; Kemal Behzatoğlu
Journal:  J Craniofac Surg       Date:  2013-05       Impact factor: 1.046

6.  Differential expression of beta 1, beta 3 and beta 4 integrins in sarcomas of the small, round, blue cell category.

Authors:  T Barth; P Möller; G Mechtersheimer
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

7.  CT and clinical findings of peripheral primitive neuroectodermal tumour in children.

Authors:  Huijuan Xiao; Fengchang Bao; Hongna Tan; Bo Wang; Wei Liu; Jianbo Gao; Xianzheng Gao
Journal:  Br J Radiol       Date:  2016-02-05       Impact factor: 3.039

8.  Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009.

Authors:  Peter M de Blank; Quinn T Ostrom; Chaturia Rouse; Yingli Wolinsky; Carol Kruchko; Joanne Salcido; Jill S Barnholtz-Sloan
Journal:  Cancer Med       Date:  2015-01-27       Impact factor: 4.452

9.  Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.

Authors:  Jiyun Shi; Di Fan; Chengyan Dong; Hao Liu; Bing Jia; Huiyun Zhao; Xiaona Jin; Zhaofei Liu; Fang Li; Fan Wang
Journal:  Theranostics       Date:  2014-01-18       Impact factor: 11.556

10.  Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study.

Authors:  Weibing Miao; Shan Zheng; Haojie Dai; Feng Wang; Xiaona Jin; Zhaohui Zhu; Bing Jia
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.